Like KLHDC3 and KLHDC4, the research conducted on the other family members indicates that targeting this subfamily could be a potential therapeutic strategy for various KLHDC‐overexpressing cancer types; however, potential inhibitors are not well documented. The gene discussed is KLHDC3; the disease is cancer.